Phio Pharmaceuticals Reports Third-Quarter 2026 Results and PH-762 Update
Phio Pharmaceuticals reported third-quarter 2026 financial results and said PH-762 reached development milestones, including cGMP manufacturing completion, treatment in a long-term toxicology study and submission of regulatory documents to the FDA.
Story updates
09:08:40 PM UTC
SquawkNews
Phio reported a Q3 2026 net loss of $4.2M versus $2.4M in Q3 2025, with cash of $10.6M at September 30, 2026 versus $21.0M at December 31, 2025. PH-762 Phase 2b initiation is expected in Q1 2027.Material DetailsContext by AI AnalystThis is a mid-cycle clinical development update: the Phase 1b trial…
09:25:12 PM UTC
SquawkNews
Phio Pharmaceuticals’ quarterly net loss widened year over year as operating expenses rose, primarily reflecting higher nonclinical toxicology, drug-substance and clinical-supply costs, along with increased regulatory and patent spending. The company continued advancing PH-762 toward a planned Phas…
PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents to FDAKing of Prussia, Pennsylvania--(. - November 5, 2026) - Phio Pharmaceuticals C…